{"id":786438,"date":"2023-09-27T09:55:31","date_gmt":"2023-09-27T13:55:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/"},"modified":"2023-09-27T09:55:31","modified_gmt":"2023-09-27T13:55:31","slug":"mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/","title":{"rendered":"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <strong>Clinical trial evaluating the Company\u2019s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81%<\/strong><\/p>\n<\/li>\n<li>\n          <strong>Pulsus Group\u2019s 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology<\/strong>\n        <\/li>\n<\/ul>\n<p>BERKELEY, Calif. and MAINZ, Germany, Sept.  27, 2023  (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will present the positive detailed results from its ColoFuture study at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sF1xPNUrgwN2UTM2iVfQ44VnetJ9k6RRtM3wlb5vOEqWkoh6TZKzxJdQaKd0B6ChnaDGYUdLnJsFFvroAnlDJFwWbUDKZBQORvdZIxxgGIJnwQmvYIv3XhtGNbX5ABtaj70DDoKx20WdbuclUOMfFWeLcikHzSPaIkuEunyT6P8=\" rel=\"nofollow noopener\" target=\"_blank\">4<sup>th<\/sup> International Conference on Gastroenterology<\/a> which occurs on October 16th &#8211; 18th in Paris, France. The ColoFuture study was a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert<sup>\u00ae<\/sup>, the Company\u2019s highly efficacious, and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories.<\/p>\n<p>&#8220;The data generated from this study represents a potentially ground-breaking milestone for CRC detection and we are excited to share the details of our findings with the attending audience of international medical experts,\u201d commented Guido Baechler, Chief Executive Officer of Mainz Biomed. \u201cMultiple novel mRNA biomarkers were identified for possible integration into our pivotal FDA PMA clinical trial, and we\u00a0look forward to comparing ColoFuture\u2019s data outcome with results from our eAArly DETECT clinical study which remains on track to report in Q4 of this year.\u201d<\/p>\n<p>\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:132.00px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Abstract<\/strong>\n          <\/td>\n<td style=\"width:469.27px;border-bottom: solid black 1pt;vertical-align: top\">QC-ICGR23-128<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132.00px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Session<\/strong><\/p>\n<p>            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:469.27px;border-bottom: solid black 1pt;vertical-align: top\">Poster session, 4<sup>th<\/sup> International Conference of Gastroenterology, Paris, France<\/p>\n<p>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132.00px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Title<\/strong>\n          <\/td>\n<td style=\"width:469.27px;border-bottom: solid black 1pt;vertical-align: top\">A novel and non-invasive mRNA and AI based early Colorectal Cancer and Advanced Adenoma detection approach &#8211; First interim data review of the international COLOFUTURE case control study<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132.00px;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Speaker<\/strong>\n          <\/td>\n<td style=\"width:469.27px;border-bottom: solid black 1pt;vertical-align: top\">Dr. Moritz Eidens<\/p>\n<p>\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132.00px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:469.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:132.00px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:469.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>The ColoFuture study was an international clinical trial assessing the performance of ColoAlert with the Company\u2019s novel mRNA markers to determine sensitivity and specificity for colorectal adenocarcinoma and advanced precancerous lesions in the colon. It included 220 subjects aged 40-85 (45% female, 55% male, average age 62.3 years) from participating centers in Germany, Norway and Denmark.\u00a0The Company reported topline results from ColoFuture in September 2023, and key highlights included a sensitivity of 94% and specificity of 97% for colorectal cancer, along with a sensitivity of 81% for advanced adenomas. The eAArly DETECT study is the U.S. component of ColoFuture which is enrolling 250 subjects across 25 sites.<\/p>\n<p>The\u00a04<sup>th<\/sup>\u00a0International Conference on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tvm4a-k3r3hjt8zVMislFmtqJoSBjHHT7LWmd39m1x3mMfS8OsxLlmGG5ybi_yIZS_kfvGZVOkuXiGifNAxisfM1R8Yi2apnp0HTv31cehhTexRHPcSi3EUKG_L-4dub6xDh6qlNUkAsVYLAdbTVqA==\" rel=\"nofollow noopener\" target=\"_blank\">Gastroenterology<\/a>\u00a0brings together world-renowned speakers including scientists, doctors, professors, examiners, instructors, and researchers to share discoveries and ground-breaking ideas in the field of gastrointestinal research.<\/p>\n<p>\n        <strong>About ColoAlert<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <br \/>ColoAlert<sup>\u00ae<\/sup>, Mainz Biomed\u2019s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert<sup>\u00ae<\/sup> detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fe1rxgtrORCUUlHssL3yJu1kJxk9cdtD6_yKrzPhkIrP3rtPRBWNS0MIrByUKJECcvVEXd-43nXIYf4Jqqy2_6ZQF3BR62k-wzn-v2yNOdSLkQcMwPEXLpbiCQDxO5TR\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>Dollinger et al., 2018<\/u><\/strong><\/a>). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert<sup>\u00ae<\/sup> will be evaluated in the FDA-registration trial \u2018ReconAAsense.\u2019 Once approved in the US, the Company\u2019s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.<\/p>\n<p>\n        <strong>About Colorectal Cancer<\/strong><br \/>\n        <br \/>Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert<sup>\u00ae<\/sup> should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.<\/p>\n<p>\n        <strong>About Mainz Biomed N.V.<\/strong><br \/>\n        <br \/>Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company\u2019s flagship product is ColoAlert<sup>\u00ae<\/sup>, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert<sup>\u00ae<\/sup> is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed\u2019s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kb3WGNS43mnKdus5N8bNnqrG6qZq-_93ofyK_fjm8a2xYmO07E2dDCRsLGQfnTDcQNFy2L53iUt4BFHhAKvS9FFRF2m4G2G0Y2EvQm9sCgg=\" rel=\"nofollow noopener\" target=\"_blank\"><u>mainzbiomed.com<\/u><\/a> or follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x-aaw-7K1bFoznS6aapHcviOLzS2heN9Od2kvka7pcKvuo6HpAyEoewE_Jsg5ney-_acQHYdqgNlUlwJVXrEguwGKius6_QL_uaUjAg9XEuNp_xzT40ec39aMc3bBfYL\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MTQ84Lw45xN3_YXzsSDFuVg2HUln52vHjdiO6ao0roVzb3uYHlakhwLIJJvokY8HfwrPDVds-jbZfFlKIWWzcrykkkU8zh7SxzspXmpm1_Q=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><u>\/X<\/u><\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yoB_E0rxjqq75K7W5eVZEn3LHMWYnOlSwNx5DcKpVbPz5-V0JQC0hHoChRq88KmDYQ0dAQ14w0yA0P4ZRP1Gc-VmmvYAjG2RwM7zeFoaB3E=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Facebook<\/u><\/a>.<\/p>\n<p>\n        <strong>For media inquiries:<\/strong>\n      <\/p>\n<p>In Europe:<br \/>MC Services AG<br \/>Anne Hennecke\/Caroline Bergmann<br \/>+49 211 529252 20<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kb3WGNS43mnKdus5N8bNnl2JHldp2qy-WX8Iftgn3pLkyV7Oz-8jc4CUh55ko4Kuwx2mhypmhxEWjVZsbIOB4JBYrpYEkYmVo3So9WQUbj-bdKfX0eBvdSWEF-dAA9qq\" rel=\"nofollow noopener\" target=\"_blank\">mainzbiomed@mc-services.eu<\/a><\/p>\n<p>In the US:<br \/>Josh Stanbury<br \/>+1 416 628 7441<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2bEn6Lids_LrZVQb0-HyLyp806QMKoKBX4k8NZcMvQu8uh6q8otsQF5dSt5hwxTB-HDHAx2DK90GcEOmc8nSYA==\" rel=\"nofollow noopener\" target=\"_blank\">josh@sjspr.co<\/a><\/p>\n<p>\n        <strong>For investor inquiries, please contact\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0h47XHUbG73iZzTQtXuqTKV_5e_IPC3YkN-crJeIYC7RuULOarNm73HuZsxpPs56-V5iH4Dzm3VUMnauuFztE9Ctf_99J4omZVT4BjH9XFc=\" rel=\"nofollow noopener\" target=\"_blank\">info@mainzbiomed.com<\/a><\/strong>\n      <\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201coutlook\u201d, and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company\u2019s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by the Company. Additional information concerning these and other factors that may impact the Company\u2019s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company\u2019s SEC filings are available publicly on the SEC\u2019s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MzRlYWZkMmEtNWFjZS00ZTQ1LThkOGMtNjk5ZjYxYzg0N2MwLTEyMzU2NDI=\/tiny\/Mainz-BioMed-NV.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Clinical trial evaluating the Company\u2019s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group\u2019s 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology BERKELEY, Calif. and MAINZ, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will present the positive detailed results from its ColoFuture study at the 4th International Conference on Gastroenterology which occurs on October 16th &#8211; 18th in Paris, France. The ColoFuture study was &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-786438","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Clinical trial evaluating the Company\u2019s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group\u2019s 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology BERKELEY, Calif. and MAINZ, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will present the positive detailed results from its ColoFuture study at the 4th International Conference on Gastroenterology which occurs on October 16th &#8211; 18th in Paris, France. The ColoFuture study was &hellip; Continue reading &quot;Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-27T13:55:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology\",\"datePublished\":\"2023-09-27T13:55:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/\"},\"wordCount\":1127,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/\",\"name\":\"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==\",\"datePublished\":\"2023-09-27T13:55:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/","og_locale":"en_US","og_type":"article","og_title":"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology - Market Newsdesk","og_description":"Clinical trial evaluating the Company\u2019s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group\u2019s 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology BERKELEY, Calif. and MAINZ, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) &#8212; Mainz Biomed N.V. (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that it will present the positive detailed results from its ColoFuture study at the 4th International Conference on Gastroenterology which occurs on October 16th &#8211; 18th in Paris, France. The ColoFuture study was &hellip; Continue reading \"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-27T13:55:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology","datePublished":"2023-09-27T13:55:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/"},"wordCount":1127,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/","name":"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==","datePublished":"2023-09-27T13:55:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDg0MTI4MiM0MDE2MTQxMDEjMjIyNDA4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-to-present-detailed-results-of-colofuture-study-at-international-conference-on-gastroenterology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=786438"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786438\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=786438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=786438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=786438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}